Adenosine Conjugated Docetaxel Nanoparticles—Proof of Concept Studies for Non-Small Cell Lung Cancer

Non-small cell lung cancer, a molecularly diverse disease, is the most prevalent cause of cancer mortality globally. Increasing understanding of the clinicopathology of the disease and mechanisms of tumor progression has facilitated early detection and multimodal care. Despite the advancements, survival rates are extremely low due to non-targeted therapeutics and correspondingly increased risk of metastasis. At some phases of cancer, patients need to face the ghost of chemotherapy. It is a difficult decision near the end of life. Such treatments have the capability to prolong survival or reduce symptoms, but can cause serious adverse effects, affecting quality of life of the patient. It is evident that many patients do not die from burden of the disease alone, but they die due to the toxic effect of treatment. Thus, increasing the efficacy is one aspect and decreasing the toxicity is another critical aspect of cancer formulation design. Through our current research, we tried to uncover both mentioned potentials of the formulation. Therefore, we designed actively targeted nanoparticles for improved therapeutics considering the overexpression of adenosine (ADN) receptors on non-small cell lung cancer (NSCLC) cells. Docetaxel (DTX), an essential therapeutic as part of combination therapy or as monotherapy for the treatment of NSCLC, was encapsulated in biodegradable poly(lactic-co-glycolic acid) nanoparticles. ADN was conjugated on the surface of nanoparticles using EDC-NHS chemistry. The particles were characterized in vitro for physicochemical properties, cellular uptake, and biocompatibility. The size and zeta potential of DTX nanoparticles (DPLGA) were found to be 138.4 ± 5.45 nm and −16.7 ± 2.3 mV which were found to change after ADN conjugation. The size was increased to 158.2 ± 6.3 nm, whereas zeta potential was decreased to −11.7 ± 1.4 mV for ADN-conjugated DTX nanoparticles (ADN-DPLGA) indicative of surface conjugation. As observed from transmission electron microscopy (TEM), the nanoparticles were spherical and showed no significant change in encapsulation efficiency even after surface conjugation. Careful and systematic optimization leads to ADN-conjugated PLGA nanoparticles having distinctive characteristic features such as particle size, surface potential, encapsulation efficacy, etc., that may play crucial roles in the fate of nanoparticles (NPs). Consequently, higher cellular uptake in the A549 lung cancer cell line was exhibited by ADN-DPLGA compared to DPLGA, illustrating the role of ADN receptors (ARs) in facilitating the uptake of NPs. Further in vivo pharmacokinetics and tissue distribution experiments revealed prolonged circulation in plasma and significantly higher lung tissue distribution than in other organs, dictating the targeting potential of the developed formulation over naïve drug and unconjugated formulations. Further, in vivo acute toxicity was examined using multiple parameters for non-toxic attributes of the developed formulation compared to other non-targeted organs. Further, it also supports the selection of biocompatible polymers in the formulation. The current study presents a proof-of-concept for a multipronged formulation technology strategy that might be used to maximize anticancer therapeutic responses in the lungs in the treatment of NSCLC. An improved therapeutic and safety profile would help achieve maximum efficacy at a reduced dose that would eventually help reduce the toxicity.

[1]  M. Tognon,et al.  Cancer biology and molecular genetics of A3 adenosine receptor , 2021, Oncogene.

[2]  S. M. Badr-Eldin,et al.  Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS , 2021, Pharmaceutics.

[3]  Sumeet Gupta,et al.  Pharmacokinetics and tissue distribution of hydrazinocurcumin in rats , 2021, Pharmacological Reports.

[4]  F. Ungaro,et al.  Multi-component bioresponsive nanoparticles for synchronous delivery of docetaxel and TUBB3 siRNA to lung cancer cells. , 2021, Nanoscale.

[5]  M. Attimarad,et al.  Topical Nanoemulgel for the Treatment of Skin Cancer: Proof-of-Technology , 2021, Pharmaceutics.

[6]  Sanyog Jain,et al.  pH sensitive liposomes assisted specific and improved breast cancer therapy using co-delivery of SIRT1 shRNA and Docetaxel. , 2020, Materials science & engineering. C, Materials for biological applications.

[7]  S. Jafari Role of Adenosine receptor in lung cancer , 2020 .

[8]  R. Tekade,et al.  Development of Metronidazole Loaded Chitosan Nanoparticles Using QbD Approach—A Novel and Potential Antibacterial Formulation , 2020, Pharmaceutics.

[9]  Manisha Pandey,et al.  Development and Optimization of Naringenin-Loaded Chitosan-Coated Nanoemulsion for Topical Therapy in Wound Healing , 2020, Pharmaceutics.

[10]  K. Jadhav,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma. , 2020, ACS biomaterials science & engineering.

[11]  P. Kesharwani,et al.  Theranostic application of nanoemulsion in chemotherapy. , 2020, Drug discovery today.

[12]  I. Estrela-Lopis,et al.  Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells , 2020, Journal of Nanobiotechnology.

[13]  R. Y. Patil,et al.  Antioxidants with Multivitamin and Mineral Supplementation Attenuates Chemotherapy or Radiotherapy-induced Oxidative Stress in Cancer Patients , 2020, Indian Journal of Pharmaceutical Education and Research.

[14]  Cornelia M. Wilson,et al.  Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. , 2020, Seminars in cancer biology.

[15]  S. Jacob,et al.  Enhancement in antinociceptive and anti-inflammatory effects of tramadol by transdermal proniosome gel , 2019, Asian journal of pharmaceutical sciences.

[16]  K. Ramanathan,et al.  Design of ALK Inhibitors for Non-Small Cell Lung Cancer – A Fragment Based Approach , 2019 .

[17]  M. Attimarad,et al.  HPMC- and PLGA-Based Nanoparticles for the Mucoadhesive Delivery of Sitagliptin: Optimization and In Vivo Evaluation in Rats , 2019, Materials.

[18]  M. Morsy,et al.  Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers , 2018, International journal of pharmaceutics.

[19]  S. Jacob,et al.  Dose translation between laboratory animals and human in preclinical and clinical phases of drug development , 2018, Drug development research.

[20]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[21]  M. Attimarad,et al.  Poly(lactic acid-co-glycolic acid) Nanospheres Improved the Oral Delivery of Candesartan Cilexetil , 2017 .

[22]  Qinghua Xu,et al.  Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin , 2017, Acta Pharmacologica Sinica.

[23]  R. Robison,et al.  Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane , 2017, OncoTargets and therapy.

[24]  A. Haddadi,et al.  Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile , 2017, International journal of nanomedicine.

[25]  H. Sugimura,et al.  Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer , 2017, Oncotarget.

[26]  M. Coelho,et al.  Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. , 2016, Colloids and surfaces. B, Biointerfaces.

[27]  Vipul Bansal,et al.  Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer , 2016, Scientific Reports.

[28]  S. Pawar,et al.  Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity. , 2015, International journal of pharmaceutics.

[29]  Wahid Khan,et al.  Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting. , 2015, International journal of pharmaceutics.

[30]  Wahid Khan,et al.  p-Aminophenyl-α-D-mannopyranoside engineered lipidic nanoparticles for effective delivery of docetaxel to brain. , 2015, Chemistry and physics of lipids.

[31]  M. Attimarad,et al.  Novel Drying Technology of Microsphere and Its Evaluation for Targeted Drug Delivery for Lungs , 2015 .

[32]  Deep Pooja,et al.  Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. , 2014, Colloids and surfaces. B, Biointerfaces.

[33]  Qi Shen,et al.  Enhanced cellular uptake of folic acid–conjugated PLGA–PEG nanoparticles loaded with vincristine sulfate in human breast cancer , 2011, Drug development and industrial pharmacy.

[34]  T. Young,et al.  The role of adenosine receptor and caveolae-mediated endocytosis in oligonucleotide-mediated gene transfer. , 2011, Biomaterials.

[35]  Kit S Lam,et al.  The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.

[36]  B. O'connor,et al.  Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects , 2008, European Respiratory Journal.

[37]  S. Holgate,et al.  Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation. , 2006, Current drug targets.

[38]  Hongzhe Sun,et al.  Transferrin-mediated gold nanoparticle cellular uptake. , 2005, Bioconjugate chemistry.

[39]  F. Fossella Docetaxel in second-line treatment of non-small-cell lung cancer. , 2002, Clinical lung cancer.

[40]  Prachi Gupta,et al.  Quantitative evaluation of targeted drug delivery systems , 1989 .